Dr. Francesco Berti describes the use of proton NMR for structural identity and conformity testing of carbohydrate-based vaccines.

Polysaccharide-protein conjugate vaccines are among the safest and most successful vaccines developed in the last 30 years.  Since the first semisynthetic chemical conjugate vaccine was licensed in the 1980’s to protect human against Haemophilus influenzae type b infection, conjugate vaccines against Neisseria meningitidis and Streptococcus pneumoniae have been developed and registered using the same approach (i.e. bacterial growth to produce capsular polysaccharide antigen and chemical coupling to carrier protein).

Physicochemical techniques are a powerful tool for the structural characterization of those vaccines. High-field Nuclear Magnetic Resonance (NMR) spectroscopy has been established as an extremely useful and robust method for tracking the industrial manufacturing process of these vaccines from polysaccharide bulk antigen through to the final formulation.

In this Bruker webinar, Dr. Francesco Berti will describe the use of proton NMR for structural identity and conformity testing of carbohydrate-based vaccines.


Scientific Director, Technical R&D
GSK Vaccines

Dr. Berti earned his bachelor and PhD degrees in Physical Chemistry at the University of Siena (Italy). He joined GSK Vaccines as a young scientist and in the following 10 years was appointed Project Leader, Lab Head, Unit Head, Head of Vaccine Chemistry and Formulation Department and Head of Antigen Design Department. In April 2018, Dr. Berti was appointed Scientific Director – Technical R&D, which is his current position. Dr. Berti has also served as a visiting scientist at the Institute of Biological Sciences in Ottawa, Canada, and at the Genomic Institute of Novartis Foundation in La Jolla, CA. For the last 15 years, he has been working on research and development of several carbohydrate-based vaccines, particularly focusing on carbohydrate- and protein-based antigens against bacterial and viral infections. He has authored and co-authored of approximately 80 published scientific papers and reviews and more than 20 patents.

Production Partner

Bruker Corporation

Bruker offers preclinical imaging solutions for a broad spectrum of application fields, such as cancer research, neuroimaging and cardiac disease.

Additional Content From Bruker Corporation

Related Content